ArticlePostepy dermatologii i alergologii2024
LED-emitted blue light improves quality of life and reduces fatigue after COVID-19 infection.
Article in Postepy dermatologii i alergologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic Immunomodulatory Effects of Full-Body Blue Light Therapy in Psoriasis Vulgaris Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite multiple clinical presentations of long COVID, the most common symptom encountered by the patients is fatigue which significantly impacts daily functioning and quality of life. There are, however, multiple unanswered questions regarding the treatment of fatigue among long COVID patients. Several studies highlighted that repetitive exposure to blue light may alleviate the fatigue in different groups of patients but the studies on the efficacy of blue light therapy in treatment of fatigue in long COVID patients are lacking. Aim: To evaluate the effects of blue light therapy in treatment of fatigue among COVID-19 survivors. Material and methods: The study comprised of 43 adults who underwent COVID-19 infection with a subjective feeling of fatigue 4 weeks after the infection. All participants underwent 10 full-body blue light irradiation for 15 min a day for 5 consecutive days each week. All participants were assessed using the Fatigue Severity Scale (FSS), Short Form 36 Vitality Subscale (SF-36) and Dermatology Life Quality Index (DLQI). Serum samples were taken to measure the levels of tryptophan, kynurenine, kynurenic acid, quinolinic acid and serotonin before and after irradiation. Results: Irradiation with blue light resulted in a significant decrease in FSS and DLQI as well as in an increase in SF-36 and serum levels of tryptophan, kynurenine and serotonin. Conclusions: Our study shows that blue light therapy could be used as adjunctive treatment of fatigue and provide an opportunity for further scientific inquiries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.